NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ONC

BeOne Medicines Ltd ADR

Jun 30 • 04:00PM ET

242.07

Dollar change +0.87
Percentage change 0.36	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: REGN AMGN VRTX GILD INCY BMRN EXEL KPTI IONS BLUE

| Held by: IBB FBT BBH AVEM ONEQ CANC CGGE DFAE CGNG AGNG

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.71	Insider Own	0.88%	Shs Outstand	109.60M	Perf Week	-6.00%
Market Cap	26.53B	Forward P/E	43.34	EPS next Y	5.59	Insider Trans	-59.58%	Shs Float	108.63M	Perf Month	-1.87%
Enterprise Value	25.00B	PEG	-	EPS next Q	0.18	Inst Own	38.43%	Short Float	1.77%	Perf Quarter	-9.47%
Income	-392.37M	P/S	6.35	EPS this Y	124.78%	Inst Trans	-11.72%	Short Ratio	4.35	Perf Half Y	33.28%
Sales	4.18B	P/B	7.47	EPS next Y	268.82%	ROA	-6.82%	Short Interest	1.92M	Perf YTD	31.05%
Book/sh	32.42	P/C	10.50	EPS next 5Y	-	ROE	-11.44%	52W High	287.88 -15.91%	Perf Year	65.30%
Cash/sh	23.06	P/FCF	-	EPS past 3/5Y	26.95% 17.26%	ROIC	-10.56%	52W Low	141.84 70.66%	Perf 3Y	54.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.96% 54.83%	Gross Margin	81.60%	Volatility	2.91% 2.74%	Perf 5Y	29.14%
Dividend TTM	-	EV/Sales	5.99	EPS Y/Y TTM	50.65%	Oper. Margin	-7.08%	ATR (14)	9.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.71	Sales Y/Y TTM	51.16%	Profit Margin	-9.40%	RSI (14)	43.12	Recom	1.16
Dividend Gr. 3/5Y	- -	Current Ratio	1.96	EPS Q/Q	100.47%	SMA20	-6.03%	Beta	0.29	Target Price	333.67
Payout	-	Debt/Eq	0.28	Sales Q/Q	48.64%	SMA50	-2.17%	Rel Volume	0.91	Prev Close	241.20
Employees	11000	LT Debt/Eq	0.06	Earnings	May 07 BMO	SMA200	7.16%	Avg Volume	441.51K	Price	242.07
IPO	Feb 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% -1.30%	Trades		Volume	402,124	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-25	Initiated	RBC Capital Mkts	Outperform	$312
Mar-03-25	Upgrade	BofA Securities	Neutral → Buy	$207 → $320
Dec-03-24	Resumed	Morgan Stanley	Overweight	$300
Sep-18-24	Initiated	JMP Securities	Mkt Outperform	$288
Feb-06-24	Resumed	JP Morgan	Overweight	$185
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy
Oct-12-21	Initiated	Bernstein	Outperform	$431
Oct-06-21	Upgrade	CLSA	Underperform → Buy
Mar-08-21	Initiated	China Renaissance	Buy
Mar-01-21	Downgrade	CLSA	Outperform → Underperform	$330 → $321
Nov-09-20	Downgrade	Ladenburg Thalmann	Buy → Neutral

Show Previous Ratings

Jun-28-25 08:35AM	BeOne Medicines price target raised to $330 from $313 at Morgan Stanley (TipRanks)
Jun-26-25 06:00AM	BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day (Business Wire)
Jun-25-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA (Business Wire)
Jun-12-25 06:00AM	BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 (Business Wire) +5.38%
Jun-11-25 04:05PM	U.S. FDA Approves Tablet Formulation of BeOnes BRUKINSA for All Approved Indications (Business Wire)
06:01AM	Loading…
06:01AM	BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 (Business Wire)
Jun-05-25 02:03PM	Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple (Investor's Business Daily)
Jun-02-25 06:00AM	BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 (Business Wire)
May-31-25 08:00AM	BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSAs Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025 (Business Wire)
May-27-25 08:30AM	BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology (Business Wire)
06:00AM	BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for Nasopharyngeal Cancer (Business Wire)
May-22-25 06:00AM	BeiGene Presents Pioneering Cancer Research at ASCO 2025 Redefining Treatment Across Hematology and Solid Tumors (Business Wire)
May-14-25 04:05PM	BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSAs Leadership and Next-Generation Innovation (Business Wire)
May-13-25 06:01AM	BeiGene to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-12-25 07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
12:05AM	Loading…
12:05AM	Trump Drug Plan Hits Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Asian Pharma Stocks (The Wall Street Journal)
May-09-25 07:52AM	BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang's Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 01:00PM	BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ... (GuruFocus.com)
May-07-25 02:05PM	BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth (Seeking Alpha)
02:04PM	BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics (Zacks)
06:00AM	BeiGene Announces First Quarter 2025 Financial Results and Business Updates (Business Wire)
Apr-29-25 03:32PM	U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene (Business Wire)
01:21PM	Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8% (Zacks)
10:08AM	Universal Health Q1 Earnings Beat on Strong Acute Care Admissions (Zacks)
Apr-24-25 01:06PM	Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings? (Investor's Business Daily)
06:20AM	Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? (Zacks)
Apr-17-25 06:01AM	BeiGene to Announce First Quarter 2025 Financial Results on May 7 (Business Wire)
Apr-16-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
10:15AM	Loading…
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) +5.38%
Apr-03-25 05:54PM	ImmunityBio: Taking Care Of Business (Seeking Alpha) -9.76%
12:37PM	BeiGene halts ociperlimab amid poor Phase III trial predictions (Clinical Trials Arena)
06:00AM	BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program (Business Wire)
Mar-31-25 06:00AM	BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (Business Wire)
Mar-18-25 07:45AM	EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors (Benzinga)
Mar-06-25 11:12AM	Q4 2024 Zymeworks Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-25 04:54AM	FDA approves BeiGenes Tevimbra plus chemo for oesophageal cancer (Pharmaceutical Technology)
Mar-04-25 06:00AM	TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy (Business Wire)
Mar-02-25 11:52AM	Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025 (Insider Monkey)
Mar-01-25 02:42PM	Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-27-25 09:30AM	BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +7.48%
06:00AM	BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates (Business Wire)
Feb-25-25 06:01AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
03:24AM	BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock? (Zacks)
Feb-13-25 06:01AM	BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27 (Business Wire)
Jan-30-25 04:23AM	ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo (Clinical Trials Arena)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
08:57AM	BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last? (Zacks)
Jan-06-25 02:00AM	BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe (Business Wire)
Dec-30-24 06:54AM	FDA approves BeiGene's TEVIMBRA combo for treating certain gastric cancers (Pharmaceutical Business Review)
06:42AM	BeiGenes Tevimbra approved in US for first-line gastric cancer treatment (Pharmaceutical Technology)
Dec-27-24 06:00AM	TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy (Business Wire)
Dec-23-24 06:00AM	BeiGene to Change Nasdaq Ticker Symbol to ONC on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 09:12AM	BeiGene inks $150M deal to follow cancer combo trail blazed by Amgen and Ideaya (FierceBiotech.com)
Dec-12-24 07:30PM	BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor (Business Wire)
Dec-09-24 08:30PM	BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets (Business Wire) -9.69%
Dec-04-24 06:00AM	BeiGene and CLL Society Partner to Advance Test Before Treat Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL (Business Wire)
Dec-03-24 04:00PM	BeiGene Gains Overweight Rating from Morgan Stanley with $300 Price Target (GuruFocus.com)
Dec-02-24 04:08PM	Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
06:01AM	BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 (Business Wire)
Nov-27-24 12:25PM	BeiGenes PD-1 drug approved in EU for first-line oesophageal cancer treatment (Pharmaceutical Technology) +7.31%
12:01PM	Why Is BeiGene Stock Trading Higher On Wednesday? (Benzinga)
06:00AM	European Commission Approves BeiGenes TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer (Business Wire)
Nov-26-24 06:01AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
Nov-19-24 07:00AM	Labcorp CFO Glenn Eisenberg Announces Plans to Retire (PR Newswire)
06:00AM	BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA (Business Wire)
Nov-15-24 12:20PM	BeiGene, Ltd. (BGNE): Among 12 High Growth Large Cap Stocks to Buy Now (Insider Monkey)
05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
Nov-14-24 06:00AM	BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer (Business Wire)
Nov-13-24 12:12AM	Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight (GuruFocus.com)
Nov-12-24 06:00AM	BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates (Business Wire) -5.56%
Nov-06-24 06:01AM	BeiGene to Present at the Jefferies London Healthcare Conference (Business Wire)
Nov-05-24 09:05AM	BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 (Business Wire)
Oct-28-24 06:00AM	BeiGene Mourns Death of Beloved Board Member Donald Glazer (Business Wire)
Oct-21-24 06:00AM	BeiGene Receives Positive CHMP Opinions for TEVIMBRA as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma (Business Wire)
Oct-16-24 06:00AM	BeiGene Highlights Waldenstrms Macroglobulinemia Innovation at IWWM 2024 (Business Wire)
Oct-10-24 10:09AM	Heres Why BeiGene, Ltd. (BGNE) Rallied in Q3 (Insider Monkey)
Oct-07-24 05:04AM	BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? (Zacks)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +5.31%
Sep-26-24 06:21PM	BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA, for Treatment of ESCC and Gastric/GEJ Cancers (Business Wire)
06:00AM	Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors (Business Wire)
Sep-25-24 03:54PM	FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients (Benzinga)
Sep-18-24 04:12AM	BeiGenes TEVIMBRA gains approval for OSCC in Israel (Pharmaceutical Technology)
Sep-17-24 07:00AM	BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy (Business Wire)
Sep-12-24 09:00PM	BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk (PR Newswire) -7.05%
Sep-09-24 07:00AM	BeiGene Announces Updates to Commercial Leadership Team (Business Wire)
01:00AM	BeiGene Highlights TEVIMBRA Data in Lung and Gastrointestinal Cancers at ESMO 2024 (Business Wire)
Aug-28-24 09:55AM	Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High? (Zacks)
06:01AM	BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-27-24 08:23AM	FDA grants fast track status to BeiGenes BGB-16673 for CLL/SLL (Pharmaceutical Technology)
Aug-26-24 09:55AM	BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
06:00AM	BeiGenes BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL (Business Wire)
Aug-23-24 02:10PM	Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer (Benzinga)
Aug-12-24 09:55AM	Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High? (Zacks)
Aug-08-24 01:05AM	Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (BGNE) (GuruFocus.com)
Aug-07-24 06:00AM	BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates (Business Wire)
Aug-01-24 04:12AM	NICE recommends BeiGenes MZL tablet for NHS use (Pharmaceutical Technology)
Jul-24-24 06:33AM	BeiGene opens biologics facility in New Jersey, US (Pharmaceutical Technology)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wang Lai	Global Head of R&D	Jun 23 '25	Sale	260.00	1,028	267,280	0	Jun 25 05:09 PM
Wu Xiaobin	President and COO	Jun 23 '25	Sale	260.00	1,363	354,380	0	Jun 25 05:08 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 24 '25	Sale	265.50	2,007	532,867	0	Jun 25 05:08 PM
OYLER JOHN	Chief Executive Officer	Jun 23 '25	Sale	261.61	3,174	830,360	0	Jun 25 05:06 PM
XIAODONG WANG	Director	Jun 24 '25	Proposed Sale	257.51	2,007	516,823		Jun 24 04:25 PM
LAI WANG	Officer	Jun 23 '25	Proposed Sale	260.00	1,028	267,280		Jun 23 04:09 PM
XIAOBIN WU	Officer	Jun 23 '25	Proposed Sale	260.00	1,363	354,380		Jun 23 04:08 PM
JOHN OYLER	Officer	Jun 23 '25	Proposed Sale	261.61	3,174	830,360		Jun 23 04:08 PM
Lee Chan Henry	SVP, General Counsel	Jun 16 '25	Sale	266.50	422	112,463	0	Jun 18 05:12 PM
Wang Lai	Global Head of R&D	Jun 16 '25	Sale	266.40	1,177	313,558	470	Jun 18 05:10 PM
Wang Lai	Global Head of R&D	Jun 17 '25	Sale	251.37	470	118,142	0	Jun 18 05:10 PM
Wu Xiaobin	President and COO	Jun 16 '25	Sale	265.52	1,543	409,694	630	Jun 18 05:08 PM
Wu Xiaobin	President and COO	Jun 17 '25	Sale	250.87	630	158,047	0	Jun 18 05:08 PM
OYLER JOHN	Chief Executive Officer	Jun 16 '25	Sale	266.05	3,680	979,046	1,460	Jun 18 05:06 PM
OYLER JOHN	Chief Executive Officer	Jun 17 '25	Sale	256.49	1,460	374,473	0	Jun 18 05:06 PM
JOHN OYLER	Officer	Jun 17 '25	Proposed Sale	256.49	1,460	374,473		Jun 17 04:20 PM
LAI WANG	Officer	Jun 17 '25	Proposed Sale	251.37	470	118,142		Jun 17 04:19 PM
XIAOBIN WU	Officer	Jun 17 '25	Proposed Sale	250.87	630	158,047		Jun 17 04:18 PM
XIAOBIN WU	Officer	Jun 16 '25	Proposed Sale	266.52	1,543	411,237		Jun 16 04:16 PM
CHAN LEE	Officer	Jun 16 '25	Proposed Sale	266.50	422	112,463		Jun 16 04:15 PM
JOHN OYLER	Officer	Jun 16 '25	Proposed Sale	266.05	3,680	979,046		Jun 16 04:14 PM
LAI WANG	Officer	Jun 16 '25	Proposed Sale	266.40	1,177	313,558		Jun 16 04:03 PM
Ball Titus B.	Principal Accounting Officer	Jun 11 '25	Sale	258.36	134	34,620	0	Jun 12 05:51 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 10 '25	Option Exercise	6.50	41,760	271,440	41,760	Jun 12 05:39 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 10 '25	Sale	262.82	41,760	10,975,316	0	Jun 12 05:39 PM
TITUS BENJAMIN BALL	Officer	Jun 11 '25	Proposed Sale	258.36	134	34,620		Jun 11 04:15 PM
Lee Chan Henry	SVP, General Counsel	Jun 06 '25	Sale	256.11	700	179,280	0	Jun 10 04:57 PM
Wang Lai	Global Head of R&D	Jun 06 '25	Sale	252.39	1,402	353,853	0	Jun 10 04:56 PM
Wu Xiaobin	President and COO	Jun 06 '25	Sale	253.15	1,934	489,591	0	Jun 10 04:55 PM
OYLER JOHN	Chief Executive Officer	Jun 06 '25	Sale	252.77	5,127	1,295,946	0	Jun 10 04:54 PM
CHAN LEE	Officer	Jun 06 '25	Proposed Sale	256.11	700	179,280		Jun 06 04:20 PM
LAI WANG	Officer	Jun 06 '25	Proposed Sale	252.39	1,402	353,853		Jun 06 04:19 PM
JOHN OYLER	Officer	Jun 06 '25	Proposed Sale	252.77	5,127	1,295,946		Jun 06 04:16 PM
XIAOBIN WU	Officer	Jun 06 '25	Proposed Sale	253.15	1,934	489,591		Jun 06 04:13 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	May 13 '25	Option Exercise	6.50	41,760	271,440	41,760	May 15 05:37 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	May 13 '25	Sale	223.50	41,760	9,333,272	0	May 15 05:37 PM
OYLER JOHN	Chief Executive Officer	May 09 '25	Option Exercise	0.50	4,055,415	2,027,708	10,154,040	May 13 05:24 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Apr 14 '25	Option Exercise	6.50	41,760	271,440	41,760	Apr 16 05:12 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Apr 14 '25	Sale	242.66	41,760	10,133,595	0	Apr 16 05:12 PM
XIAODONG WANG	Director	Apr 14 '25	Proposed Sale	230.36	125,280	28,859,501		Apr 14 04:21 PM
Wu Xiaobin	President, COO & GM China	Apr 01 '25	Option Exercise	157.14	51,921	8,159,078	51,921	Apr 03 05:04 PM
Wu Xiaobin	President, COO & GM China	Apr 01 '25	Sale	281.40	51,921	14,610,370	0	Apr 03 05:04 PM
XIAOBIN WU	Officer	Apr 01 '25	Proposed Sale	272.17	51,921	14,131,339		Apr 01 04:27 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Mar 18 '25	Option Exercise	6.50	41,760	271,440	41,760	Mar 20 04:53 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Mar 18 '25	Sale	261.28	41,760	10,911,252	0	Mar 20 04:53 PM
OYLER JOHN	Chief Executive Officer	Mar 10 '25	Option Exercise	0.96	539,032	516,776	6,098,625	Mar 12 05:02 PM
OYLER JOHN	Chief Executive Officer	Mar 10 '25	Sale	242.67	41,210	10,000,483	0	Mar 12 05:02 PM
JOHN OYLER	Officer	Mar 10 '25	Proposed Sale	242.67	41,210	10,000,480		Mar 10 04:19 PM
OYLER JOHN	Chief Executive Officer	Mar 07 '25	Option Exercise	0.96	767,337	735,208	5,600,803	Mar 07 08:17 PM
OYLER JOHN	Chief Executive Officer	Mar 07 '25	Sale	249.13	58,590	14,596,247	0	Mar 07 08:17 PM
OYLER JOHN	Chief Executive Officer	Mar 06 '25	Option Exercise	0.96	526,270	503,789	4,892,056	Mar 07 07:26 PM
OYLER JOHN	Chief Executive Officer	Mar 06 '25	Sale	259.15	40,109	10,394,329	0	Mar 07 07:26 PM
Wu Xiaobin	President, COO & GM China	Mar 05 '25	Option Exercise	126.71	51,921	6,578,658	51,921	Mar 07 07:24 PM
Wu Xiaobin	President, COO & GM China	Mar 05 '25	Sale	261.59	51,921	13,581,905	0	Mar 07 07:24 PM
JOHN OYLER	Officer	Mar 07 '25	Proposed Sale	249.13	58,590	14,596,245		Mar 07 05:14 PM
JOHN OYLER	Officer	Mar 06 '25	Proposed Sale	259.15	40,109	10,394,328		Mar 06 05:22 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Mar 04 '25	Sale	254.58	8,146	2,073,826	0	Mar 06 04:48 PM
OYLER JOHN	Chief Executive Officer	Mar 03 '25	Option Exercise	0.96	1,321,531	1,266,766	4,199,364	Mar 05 04:59 PM
OYLER JOHN	Chief Executive Officer	Mar 03 '25	Sale	244.30	101,000	24,674,638	0	Mar 05 04:59 PM
XIAOBIN WU	Officer	Mar 05 '25	Proposed Sale	257.31	51,921	13,359,793		Mar 05 04:26 PM
WANG INVESTMENT LLC	Co-Founder	Mar 04 '25	Proposed Sale	245.53	8,146	2,000,087		Mar 04 05:07 PM
HHLR Advisors, Ltd. (1)	Shareholder (1)	Mar 03 '25	Proposed Sale	271.80	2,480,000	674,064,000		Mar 03 09:31 PM
JOHN OYLER	Officer	Mar 03 '25	Proposed Sale	244.30	101,000	24,674,633		Mar 03 05:30 PM
Lee Chan Henry	SVP, General Counsel	Feb 27 '25	Sale	275.00	1,205	331,375	0	Mar 03 04:49 PM
Baker Brothers Life Sciences,	Affiliate	Feb 28 '25	Proposed Sale	260.00	671,976	174,713,760		Feb 28 09:43 PM
667, L.P.	Affiliate	Feb 28 '25	Proposed Sale	260.00	60,851	15,821,260		Feb 28 09:40 PM
BAKER BROS. ADVISORS LP	Director	Feb 28 '25	Sale	260.00	732,827	190,535,020	730,642	Feb 28 09:28 PM
CHAN LEE	Officer	Feb 27 '25	Proposed Sale	259.00	1,205	312,095		Feb 27 04:27 PM
Wang Lai	Global Head of R&D	Feb 21 '25	Sale	257.23	5,000	1,286,174	0	Feb 25 05:06 PM
Lee Chan Henry	SVP, General Counsel	Feb 21 '25	Sale	258.04	1,202	310,170	0	Feb 25 05:04 PM
CHAN LEE	Officer	Feb 21 '25	Proposed Sale	244.20	1,202	293,528		Feb 21 04:24 PM
WANG HOLDINGS LLC	Officer	Feb 21 '25	Proposed Sale	244.20	5,000	1,221,000		Feb 21 04:23 PM
Wu Xiaobin	President, COO & GM China	Feb 18 '25	Option Exercise	169.65	30,654	5,200,451	30,654	Feb 20 06:12 PM
Wu Xiaobin	President, COO & GM China	Feb 20 '25	Option Exercise	169.65	21,267	3,607,947	21,267	Feb 20 06:12 PM
Wu Xiaobin	President, COO & GM China	Feb 18 '25	Sale	240.74	30,654	7,379,531	0	Feb 20 06:12 PM
Wu Xiaobin	President, COO & GM China	Feb 20 '25	Sale	240.07	21,267	5,105,513	0	Feb 20 06:12 PM
XIAOBIN WU	Officer	Feb 18 '25	Proposed Sale	230.86	51,921	11,986,482		Feb 18 04:29 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Feb 04 '25	Option Exercise	6.50	41,760	271,440	41,760	Feb 06 04:44 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Feb 04 '25	Sale	225.69	41,760	9,424,955	0	Feb 06 04:44 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 07 '25	Option Exercise	6.50	41,760	271,440	41,760	Jan 08 05:08 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 07 '25	Sale	176.50	41,760	7,370,515	0	Jan 08 05:08 PM
XIAODONG WANG	Director	Jan 07 '25	Proposed Sale	180.64	125,280	22,630,579		Jan 07 04:18 PM
OYLER JOHN	Chief Executive Officer	Dec 14 '24	Option Exercise	0.50	1,300,000	650,000	2,978,833	Dec 17 05:02 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Dec 10 '24	Option Exercise	6.50	41,760	271,440	41,760	Dec 12 05:18 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Dec 10 '24	Sale	186.90	41,760	7,805,106	0	Dec 12 05:18 PM
BAKER BROS. ADVISORS LP	Director	Dec 09 '24	Sale	187.27	1,037,017	194,200,043	791,493	Dec 10 09:25 PM
XIAODONG WANG	Director	Dec 10 '24	Proposed Sale	207.62	41,760	8,670,211		Dec 10 04:26 PM
667, L.P.	Affiliate	Dec 09 '24	Proposed Sale	187.27	86,110	16,125,648		Dec 09 09:48 PM
Baker Brothers Life Sciences,	Affiliate	Dec 09 '24	Proposed Sale	187.27	950,907	178,074,395		Dec 09 09:48 PM
HHLR ADVISORS, LTD.	10% Owner	Dec 02 '24	Sale	200.00	17,842,500	3,568,500,000	125,045,741	Dec 04 04:06 PM
HHLR Advisors, Ltd. (1)	Shareholder (1)	Dec 02 '24	Proposed Sale	215.00	1,372,500	295,087,500		Dec 02 09:45 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 26 '24	Option Exercise	6.50	38,461	249,996	40,468	Nov 29 04:31 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 26 '24	Sale	190.10	40,468	7,693,071	0	Nov 29 04:31 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 26 '24	Sale	189.97	7,883	1,497,499	0	Nov 29 04:31 PM
XINSHENG LIAO TTEE XIAODONG WA	Officer	Nov 26 '24	Proposed Sale	190.30	7,883	1,500,135		Nov 26 04:23 PM
XIAODONG WANG	Director	Nov 26 '24	Proposed Sale	190.30	40,468	7,701,060		Nov 26 04:23 PM
PAN-OYLER FOUNDATION	Director	Nov 25 '24	Proposed Sale	190.51	1,969	375,114		Nov 25 04:39 PM
OYLER JOHN	Chief Executive Officer	Oct 08 '24	Sale	232.22	10,000	2,322,161	0	Oct 10 05:48 PM
OYLER JOHN	Chief Executive Officer	Oct 08 '24	Sale	232.22	6,175	1,433,931	0	Oct 10 05:48 PM
JOHN F OYLER	Director	Oct 08 '24	Proposed Sale	243.02	6,175	1,500,648		Oct 08 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONC

BeOne Medicines Ltd ADR

Upgrade your FINVIZ experience